Evotec SE, a life science company, has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to ...

Novo Nordisk has told government and global nonprofits that it plans to significantly downsize its manufacturing of some of ...

In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...

The European stock markets closed higher on Thursday as the Stoxx Europe 600 rose 1.19%, the Swiss Market Index gained 0.50%, France's CAC climbed 2.33%, the FTSE in London was up 0.20%, and Germany's ...

Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on ...

Evotec has joined forces with Novo Nordisk to advance the clinical and commercial manufacturing of stem cell-based therapies.

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This summary covers key developments in the pharmaceutical sector, including Pfizer's initiatives in low-income nations, challenges faced by Canadian provinces in drug treatment policies, major trial ...

The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Tagrisso (osimertinib), which is ...

Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo ...